Abstract
Matrix metalloproteinases (MMPs) belong to a family of closely related calcium- and zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix (ECM) proteins that are associated with the tumorigenic processes. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful chemotherapeutic agents for the treatment of malignant cancer, osteoarthritis, and rheumatoid arthritis. A vast number of small molecular MMPIs have been developed in recent years. Although there have been considerable preclinical and clinical studies on these inhibitors, most of the effective candidates in clinical trials, however, have yielded unsatisfactory results, thus they are as yet unavailable for use as therapeutic drugs. Currently, more efforts have been directed to the design of specific inhibitors towards certain MMP family members for selective usage. This review will focus primarily on an analysis of recent developed MMPIs that have entered preclinical or clinical trials, and recently registered patents with regard to new highly selective MMPIs in USA or patent applications related to the specific inhibitors of MMPs. We also analyze the clinical failure and discuss the possible strategies to best optimize the development of these novel agents.
Keywords: Matrix metalloproteinases (MMPs), inhibitors, specific, selectivity
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)
Volume: 5 Issue: 2
Author(s): Xun Li and Ji-Feng Wu
Affiliation:
Keywords: Matrix metalloproteinases (MMPs), inhibitors, specific, selectivity
Abstract: Matrix metalloproteinases (MMPs) belong to a family of closely related calcium- and zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix (ECM) proteins that are associated with the tumorigenic processes. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful chemotherapeutic agents for the treatment of malignant cancer, osteoarthritis, and rheumatoid arthritis. A vast number of small molecular MMPIs have been developed in recent years. Although there have been considerable preclinical and clinical studies on these inhibitors, most of the effective candidates in clinical trials, however, have yielded unsatisfactory results, thus they are as yet unavailable for use as therapeutic drugs. Currently, more efforts have been directed to the design of specific inhibitors towards certain MMP family members for selective usage. This review will focus primarily on an analysis of recent developed MMPIs that have entered preclinical or clinical trials, and recently registered patents with regard to new highly selective MMPIs in USA or patent applications related to the specific inhibitors of MMPs. We also analyze the clinical failure and discuss the possible strategies to best optimize the development of these novel agents.
Export Options
About this article
Cite this article as:
Li Xun and Wu Ji-Feng, Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs), Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936234
DOI https://dx.doi.org/10.2174/157489210790936234 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Potential Applications for Using Stem Cells in Spine Surgery
Current Stem Cell Research & Therapy Neutrophils and Eosinophils: Clinical Implications of their Appearance, Presence and Disappearance in Asthma and COPD
Current Drug Targets - Inflammation & Allergy The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19
Current Medicinal Chemistry Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?
Current Pharmacogenomics Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
Drug Metabolism Letters Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective
Current Gene Therapy Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design Natural Inhibitors against Potential Targets of Cyclooxygenase, Lipoxygenase and Leukotrienes
Combinatorial Chemistry & High Throughput Screening